Table 2. Trial group phases.
Trial type | Trials analyzed | Early Phase I | Phase I | Phase I/II | Phase II | Phase II/III | Phase III | Phase not specified |
---|---|---|---|---|---|---|---|---|
COVID-related trials | 55 | 3 (5.5%) | 8 (14.6%) | 19 (34.6%) | 19 (34.6%) | 2 (3.6%) | 1 (1.8%) | 3 (5.6%) |
Non-COVID control group (mean of three sets) | 38.7 | 1.33 (3.4%) | 10.7 (27.7%) | 10.3 (26.6%) | 7.33 (18.9%) | 0.67 (1.7%) | 3.7 (9.6%) | 4.7 (12.1%) |